Effect of paricalcitol on biochemical markers of secondary hyperparathyroidism in hemodialysis patients

被引：0
|
作者：
Zdravkovic, J. [3 ]
Georgijev, D. Ristic [3 ]
Zdravkovic, A. [5 ]
Zdravkovic, K. [2 ]
Popovic, M. [4 ]
Stojanovic, S. [1 ]
机构：
[1] Hlth Ctr Vranje, Dept Anesthesia, Novi Beograd, Serbia
[2] Hlth Ctr Vranje, Daily Chemiotherapy Hosp, Novi Beograd, Serbia
[3] Hlth Ctr Vranje, Dept Lab Med, Novi Beograd, Serbia
[4] Hlth Ctr Vranje, Dept Nephrol, Novi Beograd, Serbia
[5] Univ Nis, Fac Med, Nish, Serbia
来源：
CLINICA CHIMICA ACTA | 2024年 / 558卷
关键词：
D O I：
10.1016/j.cca.2024.118623
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
P0747
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Xiu Chen
    Feng Zhao
    Wei-Juan Pan
    Jia-Mei Di
    Wei-Nan Xie
    Ling Yuan
    Zhi Liu
    [J]. World Journal of Clinical Cases, 2021, (33) : 10172 - 10179
  • [2] Efficacy of Paricalcitol in the Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients
    Ou, Santao
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 920 - 920
  • [3] Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients
    Zawierucha, Jacek
    Malyszko, Jolanta
    Malyszko, Jacek S.
    Prystacki, Tomasz
    Marcinkowski, Wojciech
    Dryl-Rydzynska, Teresa
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (12): : 840 - 845
  • [4] Effective treatment of secondary hyperparathyroidism with paricalcitol in chronic hemodialysis patients
    Kampouris, H.
    Orfanaki, G.
    Kapsos, A.
    Rudenko, I.
    Grekas, D.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 131 - 131
  • [5] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Chen, Xiu
    Zhao, Feng
    Pan, Wei-Juan
    Di, Jia-Mei
    Xie, Wei-Nan
    Yuan, Ling
    Liu, Zhi
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (33) : 10172 - 10179
  • [6] Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients
    Pai, AB
    Lin, S
    Arruda, JAL
    Lau, AH
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2003, 26 (06): : 484 - 490
  • [7] Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
    Akizawa, Tadao
    Akiba, Takashi
    Hirakata, Hideki
    Kinugasa, Eriko
    Tominaga, Yoshihiro
    Fukagawa, Masafumi
    Yokoyama, Keitaro
    Zhang, Wuyan
    Linde, Peter G.
    Suzuki, Masashi
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (03) : 225 - 234
  • [8] COMPARISON OF PARATHYROIDECTOMIES WITH PARICALCITOL OR CINACALCET FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN HEMODIALYSIS PATIENTS
    Walton, Surrey M.
    Schumock, Glen T.
    Lee, Todd A.
    Marx, Steven E.
    Audhya, Paul
    Andress, Dennis L.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A78 - A78
  • [9] Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Ross, Edward A.
    Tian, Jin
    Abboud, Hanna
    Hippensteel, Richard
    Melnick, Joel Z.
    Pradhan, Rajendra S.
    Williams, Laura A.
    Hamm, L. Lee
    Sprague, Stuart M.
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (01) : 97 - 106
  • [10] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Rabinovich, MB
    Walton, T
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 1465 - 1465
12345